Contrasting Catasys (NASDAQ:CATS) & Emmaus Life Sciences (NASDAQ:EMMA)
Catasys (NASDAQ:CATS) and Emmaus Life Sciences (NASDAQ:EMMA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Risk and Volatility
Catasys has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Catasys and Emmaus Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Emmaus Life Sciences||0||0||0||0||N/A|
Catasys currently has a consensus target price of $21.00, suggesting a potential upside of 36.36%. Given Catasys’ higher possible upside, equities research analysts plainly believe Catasys is more favorable than Emmaus Life Sciences.
Institutional and Insider Ownership
17.3% of Catasys shares are held by institutional investors. Comparatively, 0.1% of Emmaus Life Sciences shares are held by institutional investors. 60.8% of Catasys shares are held by company insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Catasys and Emmaus Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Emmaus Life Sciences||-489.28%||-547.81%||-224.45%|
Earnings and Valuation
This table compares Catasys and Emmaus Life Sciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catasys||$15.18 million||16.79||-$14.21 million||($0.89)||-17.30|
|Emmaus Life Sciences||$1.32 million||121.18||-$9.59 million||($11.16)||-0.30|
Emmaus Life Sciences has lower revenue, but higher earnings than Catasys. Catasys is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.
Catasys beats Emmaus Life Sciences on 9 of the 13 factors compared between the two stocks.
Catasys, Inc. provides big data predictive analytics, artificial intelligence and telehealth, combined with human intervention services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company's OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services. Its OnTrak solution combines medical and psychosocial treatments with elements of traditional disease management, case management, and ongoing member support to help organizations treat and manage populations struggling with substance dependence, depression, and anxiety to improve their health and thereby decrease their health care costs. Catasys, Inc.'s OnTrak solution includes various components, such as identification of impactable members, member engagement, enrollment/referral, provider network, outpatient medical treatment, outpatient psychosocial treatment, care coaching, monitoring and reporting, and proprietary Web-based clinical information platform. The company was formerly known as Hythiam, Inc. and changed its name to Catasys, Inc. in March 2011. Catasys, Inc. was founded in 2000 and is based in Los Angeles, California.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with MarketBeat.com's FREE daily email newsletter.